Current Active Trials
ATMOSPHERE - Principal Investigator: Dr. Gregory Searles
Evaluate the effects of aliskiren (a renin blocker) and aliskerin/ enalapril combination therapy on top of conventional CHF therapy.
BRUISE CONTROL - Principal Investigator: Dr. Satish Toal
Evaluate the use of continuation of Coumadin at the time of Pacemaker or Implantable Defibrillator device implantation surgery, in patients with moderate to high risk of thrombo-embolic events.
CAIN-003 - Principal Investigator: Dr. Robert Teskey
Evaluating plaque burden as measured by intravascular ultrasound (IVUS) and carotid ultrasound in order to assess correlations between vascular beds, imaging technologies and major cardiovascular events.
GENESIS PRAXY - Principal Investigator: Dr. Peter Fong
The purpose of this study is to explore sex differences in key factors (behavioural, environmental, psychosocial, clinical and biological) of the presentation and prognosis of early heart attacks, as well as differences in health services utilization, satisfaction with care and quality of life.
TAO - Principal Investigator: Dr. Sohrab Lutchmedial
The purpose of this study is to evaluate the effectiveness and the possible risks of Otamixaban (a novel anticoagulant) compared to unfractionated heparin (well-known standard blood thinner) and eptifibatide (intravenous antiplatelet medication), on a background of aspirin and clopidogrel (Oral antiplatelet medication).
TRIPLET -Principal Investigator: Dr. Sohrab Lutchmedial
Evaluate the use of Prasugrel 30 or 60mg loading dose administered during PCI, with and without a prior loading dose of clopidogrel on platelet inhibition in patients presenting with ACS
VELETI II -Principal Investigator: Dr. Vernon Paddock
Evaluate the efficacy of stenting moderate SVG lesions with paclitaxel-eluding stents on reducing the first occurrence of the composite of cardiac death, MI, or repeat revascularization related to the target SVG over a minimum 2 year follow up.
VISTA 16 -Principal Investigator: Dr Colin Barry
Evaluating the safety and efficacy of short term A-002 (investigational anti inflammatory) treatment when added to atorvastatin and standard of care in subjects with an acute coronary syndrome.